EPIX

ESSA Pharma Inc. [EPIX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

EPIX Stock Summary

Top 10 Correlated ETFs

EPIX

Top 10 Correlated Stocks

EPIX

In the News

EPIX Financial details

Company Rating
-
Market Cap
343.29M
Income
-25.81M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
50
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-11.7
Forward P/E
-
PEG
4.46
P/S
-
P/B
2.13
P/C
-
P/FCF
-15.73
Quick Ratio
42.41
Current Ratio
42.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.59
EPS next Y
-
EPS next Q
-
EPS this Y
-25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
16.67%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-66.67%
Inst Own
-
Inst Trans
-
ROA
-18%
ROE
-17%
ROC
-0.18%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.56-11.67
52W High
-85.45%
52W Low
-20%
RSI
36
Rel Volume
0.03
Avg Volume
149.85K
Volume
3.96K
Perf Week
-4.76%
Perf Month
-9.09%
Perf Quarter
-77.14%
Perf Half Y
-70.26%
-
-
-
-
Beta
1.694
-
-
Volatility
0.03%, 0.04%
Prev Close
-2.44%
Price
1.6
Change
-2.44%

Something similar

Top by Market Cap
AVGO
VTSAX
META
ABEA.DE
MIX.JO
Top Correlated ETFs
BBP
IDNA
Top Correlated Stocks
AMRN
SAUHY
KRON
ON
INO
Similar Market Cap
XDWC.L
HINT.L
VPCB
HXDM.TO
EML

Company Profile

Healthcare Biotechnology
  • Volume Average 149.85K
  • Market Capitalization 343.29M
  • Employee 50
  • CEO Dr. David Ross Parkinson M.D.
  • Headquarters Vancouver,BC,CA
  • IPO Date 2015-03-13
  • Website https://www.essapharma.com

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.